Innovation in Pharmacy
Organizer Committee IPAP18 – Salamanca
This book contains the summaries of the "Innovations in Pharmacy: Advances and Perspectives" that took place in Salamanca (Spain) in September 2018. The early science of chemistry and microbiology were the source of most drugs until the revolution of genetic engineering in the mid 1970s. Then biotechnology made available novel protein agents such as interferons, blood factors and monoclonal antibodies that have changed the modern pharmacy. Over the past year, a new pharmacy of oligonucleotides has emerged from the science of gene expression such as RNA splicing and RNA interference. The ability to design therapeutic agents from genomic sequences will …
This book contains the summaries of the "Innovations in Pharmacy: Advances and Perspectives" that took place in Salamanca (Spain) in September 2018.
The early science of chemistry and microbiology were the
source of most drugs until the revolution of genetic engineering in the mid
1970s. Then biotechnology made available novel protein agents such as
interferons, blood factors and monoclonal antibodies that have changed the
modern pharmacy. Over the past year, a new pharmacy of oligonucleotides has
emerged from the science of gene expression such as RNA splicing and RNA
interference. The ability to design therapeutic agents from genomic sequences
will transform treatment for many diseases. The science that created this
advance and its future promise will be discussed.
Phillip Allen Sharp is an American geneticist and
molecular
biologist who co-discovered RNA splicing. He shared the 1993 Nobel Prize in Physiology
or Medicine
with Richard J.
Roberts for “the discovery that genes in eukaryotes are not contiguous strings but
contain introns,
and that the splicing of messenger RNA to delete those introns
can occur in different ways, yielding different proteins from the same DNA sequence. He works
in Institute Professor Koch Institute for Integrative Cancer Research,
Massachusetts Institute of Technology (MIT), Cambridge, MA, US.
Este libro recoge los resúmenes de la «Innovation in
Pharmacy: Advances and Perspectives» que tuvo lugar en Salamanca (España) en
septiembre de 2018. La ciencia primitiva de la química y la microbiología fue
la fuente de la mayoría de las drogas hasta la revolución de la ingeniería
genética a mediados de la década de 1970. Luego, la biotecnología puso a
disposición agentes proteínicos novedosos como interferones, factores
sanguíneos y anticuerpos monoclonales que han cambiado la farmacia moderna.
Durante el año pasado, surgió una nueva farmacia de oligonucleótidos a partir
de la ciencia de la expresión génica, como el empalme de ARN y la interferencia
de ARN. La capacidad de diseñar agentes terapéuticos a partir de secuencias
genómicas transformará el tratamiento de muchas enfermedades. La ciencia que
creó este avance y su promesa futura será discutida. Phillip Allen Sharp es un
genetista y biólogo molecular estadounidense que co-descubrió el empalme de
ARN. Compartió el Premio Nobel de 1993 en Fisiología o Medicina con Richard J.
Roberts por "el descubrimiento de que los genes en eucariotas no son
cadenas contiguas, sino que contienen intrones, y que el empalme del ARN
mensajero para eliminar esos intrones puede ocurrir de diferentes maneras,
produciendo diferentes proteínas de la misma secuencia de ADN. Trabaja en el
Instituto Profesor Koch Institute for Integrative Cancer Research, Instituto
Tecnológico de Massachusetts (MIT), Cambridge, MA, EE.UU.
Leer másLeer menos
